The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00. According to TipRanks, Weston is ranked #1736 out of 9162 analysts ...

In a significant stride within the pharmaceutical industry, Midtown's own Schrödinger has clinched a deal with healthcare ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...

Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.

Shyra Gardai, chief scientific officer at the molecular glue start-up EpiBiologics, says Big Pharma’s recent interest in glue ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the ...